
Matthew Gordon Katcoff
Examiner (ID: 18871, Phone: (571)270-1415 , Office: P/3725 )
| Most Active Art Unit | 3725 |
| Art Unit(s) | 3725 |
| Total Applications | 1176 |
| Issued Applications | 799 |
| Pending Applications | 89 |
| Abandoned Applications | 315 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17641960
[patent_doc_number] => 20220169698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => Compositions and Methods for Treating Cancer with DuoCARs
[patent_app_type] => utility
[patent_app_number] => 17/540377
[patent_app_country] => US
[patent_app_date] => 2021-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44437
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17540377
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/540377 | Compositions and methods for treating cancer with DuoCARs | Dec 1, 2021 | Issued |
Array
(
[id] => 18406108
[patent_doc_number] => 20230167459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => COMPOSITIONS AND METHODS FOR EXPRESSION OF IL-12 AND IL-1RA
[patent_app_type] => utility
[patent_app_number] => 17/537211
[patent_app_country] => US
[patent_app_date] => 2021-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17537211
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/537211 | Compositions and methods for expression of IL-12 and IL-1RA | Nov 28, 2021 | Issued |
Array
(
[id] => 17611541
[patent_doc_number] => 20220153820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING AND SUPPRESSING ALLERGIC RESPONSES
[patent_app_type] => utility
[patent_app_number] => 17/529513
[patent_app_country] => US
[patent_app_date] => 2021-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7729
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529513
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/529513 | COMPOSITIONS AND METHODS FOR TREATING AND SUPPRESSING ALLERGIC RESPONSES | Nov 17, 2021 | Abandoned |
Array
(
[id] => 19601434
[patent_doc_number] => 20240392314
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS
[patent_app_type] => utility
[patent_app_number] => 18/251737
[patent_app_country] => US
[patent_app_date] => 2021-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251737
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/251737 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | Nov 1, 2021 | Pending |
Array
(
[id] => 18955491
[patent_doc_number] => 20240043818
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => Engineered Cells for Increased Collagen Production
[patent_app_type] => utility
[patent_app_number] => 18/031486
[patent_app_country] => US
[patent_app_date] => 2021-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15475
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -56
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031486
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/031486 | Engineered Cells for Increased Collagen Production | Oct 14, 2021 | Pending |
Array
(
[id] => 18636432
[patent_doc_number] => 11761020
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-19
[patent_title] => Recombinant adeno-associated virus vectors with CD14 promoter and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/501973
[patent_app_country] => US
[patent_app_date] => 2021-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 20
[patent_no_of_words] => 13986
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501973
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/501973 | Recombinant adeno-associated virus vectors with CD14 promoter and use thereof | Oct 13, 2021 | Issued |
Array
(
[id] => 17664192
[patent_doc_number] => 11357868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
[patent_app_type] => utility
[patent_app_number] => 17/499567
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 125
[patent_figures_cnt] => 128
[patent_no_of_words] => 23698
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17499567
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/499567 | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor | Oct 11, 2021 | Issued |
Array
(
[id] => 17837794
[patent_doc_number] => 20220275099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/498520
[patent_app_country] => US
[patent_app_date] => 2021-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 244
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498520
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/498520 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY | Oct 10, 2021 | Abandoned |
Array
(
[id] => 19256304
[patent_doc_number] => 12016328
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-25
[patent_title] => PH adjustment to improve thaw recovery of cell banks
[patent_app_type] => utility
[patent_app_number] => 17/497330
[patent_app_country] => US
[patent_app_date] => 2021-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 14
[patent_no_of_words] => 12522
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17497330
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/497330 | PH adjustment to improve thaw recovery of cell banks | Oct 7, 2021 | Issued |
Array
(
[id] => 17664191
[patent_doc_number] => 11357867
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
[patent_app_type] => utility
[patent_app_number] => 17/495949
[patent_app_country] => US
[patent_app_date] => 2021-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 125
[patent_figures_cnt] => 125
[patent_no_of_words] => 23712
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/495949 | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor | Oct 6, 2021 | Issued |
Array
(
[id] => 19884177
[patent_doc_number] => 12269870
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-08
[patent_title] => Antigen binding regions against fibronectin type III domains and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 17/493032
[patent_app_country] => US
[patent_app_date] => 2021-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 32
[patent_no_of_words] => 21738
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493032
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/493032 | Antigen binding regions against fibronectin type III domains and methods of using the same | Oct 3, 2021 | Issued |
Array
(
[id] => 17563425
[patent_doc_number] => 20220127574
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => Universal Killer T-Cell
[patent_app_type] => utility
[patent_app_number] => 17/483484
[patent_app_country] => US
[patent_app_date] => 2021-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12851
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/483484 | Universal Killer T-Cell | Sep 22, 2021 | Abandoned |
Array
(
[id] => 17444170
[patent_doc_number] => 20220064675
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
[patent_app_type] => utility
[patent_app_number] => 17/479577
[patent_app_country] => US
[patent_app_date] => 2021-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -69
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479577
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/479577 | RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS | Sep 19, 2021 | Pending |
Array
(
[id] => 17428382
[patent_doc_number] => 20220056090
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => AAV-EPO FOR TREATING COMPANION ANIMALS
[patent_app_type] => utility
[patent_app_number] => 17/472037
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472037
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/472037 | AAV-EPO for treating companion animals | Sep 9, 2021 | Issued |
Array
(
[id] => 17314904
[patent_doc_number] => 20210403952
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/467425
[patent_app_country] => US
[patent_app_date] => 2021-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 106529
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467425
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/467425 | METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF | Sep 5, 2021 | Abandoned |
Array
(
[id] => 17444169
[patent_doc_number] => 20220064674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => CD62L specific lentiviral vector particle for targeted transduction of T cell subsets
[patent_app_type] => utility
[patent_app_number] => 17/465734
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11522
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465734
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/465734 | CD62L specific lentiviral vector particle for targeted transduction of T cell subsets | Sep 1, 2021 | Issued |
Array
(
[id] => 17704989
[patent_doc_number] => 20220204995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => NON-DISRUPTIVE GENE TARGETING
[patent_app_type] => utility
[patent_app_number] => 17/458044
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27182
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458044
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/458044 | NON-DISRUPTIVE GENE TARGETING | Aug 25, 2021 | Abandoned |
Array
(
[id] => 18647815
[patent_doc_number] => 20230293590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => CELLULAR COMPOSITIONS AND METHODS OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/041330
[patent_app_country] => US
[patent_app_date] => 2021-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19288
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041330
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/041330 | CELLULAR COMPOSITIONS AND METHODS OF TREATMENT | Aug 9, 2021 | Pending |
Array
(
[id] => 18737981
[patent_doc_number] => 20230346884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => Molecular Targets for Modulation of Dissociative and Associative States
[patent_app_type] => utility
[patent_app_number] => 18/019423
[patent_app_country] => US
[patent_app_date] => 2021-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019423
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019423 | Molecular Targets for Modulation of Dissociative and Associative States | Aug 8, 2021 | Pending |
Array
(
[id] => 19076714
[patent_doc_number] => 11946065
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB
[patent_app_type] => utility
[patent_app_number] => 17/387035
[patent_app_country] => US
[patent_app_date] => 2021-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 33
[patent_no_of_words] => 21637
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387035
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/387035 | Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB | Jul 27, 2021 | Issued |